TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18595435

Group type: EXPERIMENTAL
Intervention: eszopiclone 1 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: eszopiclone 2 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: eszopiclone 2.5 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: eszopiclone 3 mg
Number of subjects: 65

Group type: COMPARATOR
Intervention: zolpidem 10 mg
Number of subjects: 65
Study: 11527889

Group type: EXPERIMENTAL
Intervention: 1 mg dexamethasone
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 9390614

Group type: EXPERIMENTAL
Intervention: I.V. fentanyl 2 microg/kg, followed by an infusion at the rate of 25 ng x kg(‐1) x min(‐1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl injection and infusion at the same administration regimen as Group II
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bolus injections of both epidural and intravenous saline, followed by both epidural and I.V. infusions at the rate of 0.2 mL x kg(‐1) h(‐1)
Number of subjects: 50
Study: 7955996

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes subjects
Number of subjects: 97

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 97
Study: 3116847

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy after conservative breast surgery plus irradiation
Number of subjects: 764

Group type: COMPARATOR
Intervention: Modified radical mastectomy
Number of subjects: 764
Study: 28382755

Group type: EXPERIMENTAL
Intervention: Small change behavioral weight loss intervention alone
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Small change behavioral weight loss intervention with positive affect/self‐affirmation (PA/SA)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Small change PA/SA intervention
Number of subjects: 405

Group type: COMPARATOR
Intervention: Small change approach alone
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 405
Study: 25409287

Group type: EXPERIMENTAL
Intervention: Telemedicine-based collaborative care (TOP)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 265
Study: 23298183

Group type: EXPERIMENTAL
Intervention: Mat Pilates
Number of subjects: 86

Group type: COMPARATOR
Intervention: Equipment-based Pilates
Number of subjects: 86
Study: 21910335

Group type: EXPERIMENTAL
Intervention: Thermotherapy combined with thoracic injection of lentinan
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lentanian thoracically injected (Control)
Number of subjects: 60
Study: 17512156

Group type: EXPERIMENTAL
Intervention: Contingency management plus (CM+)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Contingency management (CM)
Number of subjects: 206
Study: 16469112

Group type: EXPERIMENTAL
Intervention: lumiracoxib 400 mg/day (n = 144)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: celecoxib 200 mg twice daily (n = 145)
Number of subjects: 364

Group type: COMPARATOR
Intervention: placebo (n = 75)
Number of subjects: 364
Study: 12846090

Group type: EXPERIMENTAL
Intervention: Combined conservative treatment (antibacterial therapy, transcutaneous laser irradiation of the suprapubic region using intravesical methods)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined conservative treatment plus transurethral resection (TUR) of the urinary bladder mucosa
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (urodynamic tests: uroflowmetry, sphincterometry, electromyography of the urinary bladder muscles)
Number of subjects: 60
Study: 10607324

Group type: EXPERIMENTAL
Intervention: Terbinafine (4 weeks) followed by placebo (4 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Griseofulvin (8 weeks)
Number of subjects: 50
Study: 9410297

Group type: EXPERIMENTAL
Intervention: Treadmill test
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Stairways running
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Auscultation
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cycloergometer test
Number of subjects: 55
Study: 1283663

Group type: EXPERIMENTAL
Intervention: Malto-dextrin/glycine ORS
Number of subjects: 31

Group type: COMPARATOR
Intervention: Glucose-based ORS (WHO)
Number of subjects: 31
Study: 29051989

Group type: EXPERIMENTAL
Intervention: Iguratimod 3.125 to 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iguratimod 25, 50, 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iguratimod 50 mg (multiple doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iguratimod 50 mg (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iguratimod 50 mg (fed group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iguratimod 50 mg (fasted group)
Number of subjects: 0
Study: 27077129

Group type: EXPERIMENTAL
Intervention: Intracavernous injection of autologous adipose-derived regenerative cells (ADRCs)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intracavernous injection of ADRCs in continent men
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intracavernous injection of ADRCs in incontinent men
Number of subjects: 17
Study: 26682224

Group type: EXPERIMENTAL
Intervention: Biosimilar trastuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference product trastuzumab
Number of subjects: 0
Study: 23817594

Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (n = 27)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham condition (n = 28)
Number of subjects: 55
Study: 20956838

Group type: EXPERIMENTAL
Intervention: Piezoelectric pedometers
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Spring‐levered pedometers
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Walking speed (slower and faster)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Adults with Down syndrome
Number of subjects: 44

Group type: COMPARATOR
Intervention: Adults without a disability
Number of subjects: 44
Study: 18303965

Group type: EXPERIMENTAL
Intervention: Iloperidone 24 mg/day
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study: 16968509

Group type: EXPERIMENTAL
Intervention: Endoscopic biliary drainage with metal stent insertion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Surgical drainage procedure (choledochojejunostomy and gastrojejunostomy)
Number of subjects: 30
Study: 12939735

Group type: EXPERIMENTAL
Intervention: Intensive multifactorial intervention
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 160
Study: 10689152

Group type: EXPERIMENTAL
Intervention: Live attenuated VZV vaccine (Oka 3200)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Live attenuated VZV vaccine (Oka 8500)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Live attenuated VZV vaccine (Oka 41650)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (Pneumo 23 vaccine)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Live attenuated VZV vaccine (all groups)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Live attenuated VZV vaccine
Number of subjects: 200
Study: 9490230

Group type: EXPERIMENTAL
Intervention: Use of epistemological indicators during physiotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional physiotherapy methods
Number of subjects: 20
Study: 1286054

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural meperidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional intramuscular meperidine
Number of subjects: 60
Study: 3889078

Group type: EXPERIMENTAL
Intervention: Isocarboxazid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31392213

Group type: EXPERIMENTAL
Intervention: Faroese chain dance intervention (twice‐weekly sessions for 6 weeks, 30 min for first 3 weeks, 45 min for last 3 weeks)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Faroese chain dance intervention
Number of subjects: 27
Study: 28856403

Group type: COMPARATOR
Intervention: Transurethral indwelling catheterization (TIC)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Clean intermittent catheterization (CIC)
Number of subjects: 85
Study: 26333044

Group type: EXPERIMENTAL
Intervention: Secondary prevention using 800 mcg sublingual misoprostol administered to women with postpartum blood loss ≥350 ml
Number of subjects: 92

Group type: COMPARATOR
Intervention: Universal prophylaxis using 600 mcg oral misoprostol administered to all women during the third stage of labour
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Secondary prevention
Number of subjects: 92

Group type: COMPARATOR
Intervention: Primary prevention
Number of subjects: 92
Study: 24937024

Group type: EXPERIMENTAL
Intervention: Aerobic physical exercise (walking with strides) three times a week or more
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (continued as normal)
Number of subjects: 157
Study: 21951336

Group type: EXPERIMENTAL
Intervention: Early infarct
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Both early and late infarct
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Late infarct only
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Duration of artery occlusion during surgery
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Admission plasma glucose level
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Amount of subarachnoid blood
Number of subjects: 173
Study: 20451181

Group type: EXPERIMENTAL
Intervention: Metformin and clomiphene citrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 0
Study: 19393260

Group type: EXPERIMENTAL
Intervention: Cues with negative Weber contrast between 6% and 100%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High contrast motion stimuli
Number of subjects: 0
Study: 15902892

Group type: EXPERIMENTAL
Intervention: 3D‐RA with 180 degrees rotation
Number of subjects: 22

Group type: COMPARATOR
Intervention: 3D‐RA with 160 degrees rotation and 1.4-mm catheter
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 22
Study: 14694856

Group type: EXPERIMENTAL
Intervention: Geriatric rehabilitation programmes for stroke patients (6 papers, 1138 patients)
Number of subjects: 9496

Group type: EXPERIMENTAL
Intervention: Geriatric rehabilitation for hip fractures (7 articles, 2414 patients)
Number of subjects: 9496

Group type: COMPARATOR
Intervention: Geriatric rehabilitation in acute admissions (10 studies, 4683 patients)
Number of subjects: 9496

Group type: EXPERIMENTAL
Intervention: Geriatric programmes in nursing homes, day hospitals, and in-home services (7 studies, 1261 patients)
Number of subjects: 9496
Study: 10329808

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray 0.14 mg per nostril twice daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cetirizine tablets 10 mg every day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8534682

Group type: EXPERIMENTAL
Intervention: Peritoneal equilibration test (PET) performed twice
Number of subjects: 19

Group type: COMPARATOR
Intervention: Peritoneal equilibration test (PET)
Number of subjects: 19
Study: 1938800

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.4 mg/kg/day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Thioridazine (1.75 mg/kg/day)
Number of subjects: 27
Study: 7049304

Group type: EXPERIMENTAL
Intervention: Intravesical doxorubicin (Adriamycin)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Doxorubicin and urokinase
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study: 31376167

Group type: EXPERIMENTAL
Intervention: Professional tooth cleaning before scaling and root planing (SRP)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) without professional tooth cleaning
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Professional tooth cleaning before SRP
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no professional tooth cleaning)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 30277655

Group type: COMPARATOR
Intervention: GSK3179106 single-dose (10 mg to 800 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: GSK3179106 repeat-dose (5 mg to 100 mg QD and 100 mg to 200 mg BID for 14 days)
Number of subjects: 62

Group type: COMPARATOR
Intervention: GSK3179106 (single doses up to 800 mg and repeat doses up to 400 mg)
Number of subjects: 62
Study: 29241909

Group type: EXPERIMENTAL
Intervention: Hyoscine butyl-bromide (20 mg in 1 ml)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Normal saline (1 ml)
Number of subjects: 160
Study: 25695468

Group type: EXPERIMENTAL
Intervention: Emotion and Meaning Message
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Facts and Information Message
Number of subjects: 60
Study: 24359041

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus oxytocin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clomiphene citrate plus hCG
Number of subjects: 100
Study: 21647560

Group type: EXPERIMENTAL
Intervention: S-1 with concurrent radiotherapy
Number of subjects: 50
Study: 19647523

Group type: EXPERIMENTAL
Intervention: Personalized feedback summary
Number of subjects: 61

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 61
Study: 18089875

Group type: EXPERIMENTAL
Intervention: Cetuximab plus gemcitabine/platinum (cisplatin or carboplatin)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Chemotherapy alone (gemcitabine/platinum without cetuximab)
Number of subjects: 131
Study: 16113546

Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 634

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 634
Study: 11966928

Group type: EXPERIMENTAL
Intervention: Professional toothbrusher
Number of subjects: 24

Group type: COMPARATOR
Intervention: Two brushes
Number of subjects: 24
Study: 10464830

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol 0.2 mg four times daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg four times daily
Number of subjects: 32
Study: 7589374

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 50 micrograms b.i.d.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Inhaled salbutamol 400 micrograms b.i.d.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Asthma Quality of Life Questionnaire (AQLQ)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Living With Asthma Questionnaire (LWAQ)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sickness Impact Profile (SIP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rating Scale (RS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Standard Gamble (SG) utilities
Number of subjects: 120
Study: 2304407

Group type: EXPERIMENTAL
Intervention: Walking at 4.8 kph
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Jogging at 9.6 kph
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Jogging at 9.6 kph, 10% grade
Number of subjects: 24
Study: 6268269

Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy and irradiation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Delayed chemotherapy following radiotherapy recurrence
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Chemotherapy groups
Number of subjects: 70

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lower doses of irradiation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Inadequate portals
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Adequate irradiation fields
Number of subjects: 70
Study: 31449577

Group type: EXPERIMENTAL
Intervention: Platform-switched implant
Number of subjects: 20

Group type: COMPARATOR
Intervention: Platform-matched implant
Number of subjects: 20
Study: 27956033

Group type: EXPERIMENTAL
Intervention: Cryotherapy (application of a bag of crushed ice for 20 minutes)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 50
Study: 25819187

Group type: EXPERIMENTAL
Intervention: Angio-guided provisional side-branch stenting
Number of subjects: 320

Group type: COMPARATOR
Intervention: FFR-guided provisional side-branch stenting
Number of subjects: 320
Study: 23721147

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT) with simultaneous-integrated boost and weekly cisplatin 40 mg/m² (median 6 cycles)
Number of subjects: 45
Study: 21855223

Group type: EXPERIMENTAL
Intervention: Acute nicotine administration (placebo, low, or high dose nicotine patch)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Chronic smoking (cigarette smoking group)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Non-smoking controls (placebo or low dose)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Acute nicotine administration
Number of subjects: 86
Study: 19151048

Group type: EXPERIMENTAL
Intervention: Levosimendan (24 microg kg(‐1) administered as a slow i.v. bolus over 10 min)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 17943675

Group type: EXPERIMENTAL
Intervention: Intensive gait-oriented physiotherapy
Number of subjects: 22
Study: 15475130

Group type: EXPERIMENTAL
Intervention: Ankle brace worn on the supporting leg
Number of subjects: 10

Group type: COMPARATOR
Intervention: No ankle brace
Number of subjects: 10
Study: 10841002

Group type: EXPERIMENTAL
Intervention: Insulin glargine[15]
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Insulin glargine[80]
Number of subjects: 24

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Insulin glargine[30]
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 24
Study: 10174312

Group type: EXPERIMENTAL
Intervention: Tiludronic acid (400 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etidronic acid
Number of subjects: 0
Study: 1612505

Group type: EXPERIMENTAL
Intervention: CAP5 (5 cycles of cyclophosphamide, doxorubicin, and cisplatin)
Number of subjects: 78

Group type: COMPARATOR
Intervention: CAP10 (10 cycles of cyclophosphamide, doxorubicin, and cisplatin)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: CAP5
Number of subjects: 78
Study: 6584449

Group type: EXPERIMENTAL
Intervention: Calcium (1 g) daily for 180 days
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo tablets daily for 180 days
Number of subjects: 66
Study: 31626654

Group type: EXPERIMENTAL
Intervention: Phlebotomus guggisbergi
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Phlebotomus saevus sensu lato
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Overall sandfly population
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Phlebotomus guggisbergi and Phlebotomus saevus sensu lato
Number of subjects: 729
Study: 30041656

Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (variety of games related to attention, memory, visual-spatial ability, and executive function)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 600
Study: 25790761

Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation
Number of subjects: 60
Study: 1458768

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1,2‐GDN
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1,3‐GDN
Number of subjects: 9
Study: 22697444

Group type: EXPERIMENTAL
Intervention: BA-TE in-person
Number of subjects: 40

Group type: COMPARATOR
Intervention: BA-TE HBT
Number of subjects: 40
Study: 20352355

Group type: EXPERIMENTAL
Intervention: Economic dependence on a male partner
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sexual assertiveness
Number of subjects: 0
Study: 18684261

Group type: EXPERIMENTAL
Intervention: LV lead implanted at the lateral or posterolateral wall (group A)
Number of subjects: 77

Group type: COMPARATOR
Intervention: LV lead implanted at the anterior or anterolateral wall (group B)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Overall mortality in group A
Number of subjects: 77
Study: 15816999

Group type: EXPERIMENTAL
Intervention: Educational program for preventive healthcare professionals in intervention municipalities.
Number of subjects: 4060

Group type: COMPARATOR
Intervention: Control group with no education for healthcare professionals.
Number of subjects: 4060
Study: 12891225

Group type: EXPERIMENTAL
Intervention: 125 mg aprepitant on day 1 and then 80 mg/d on days 2 to 5
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 40 mg aprepitant on day 1 and then 25 mg/d on days 2 to 5
Number of subjects: 16
Study: 10374861

Group type: EXPERIMENTAL
Intervention: CML-type mRNA expression in CML patients
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: ALL-type mRNA expression in CML patients
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: BCR/ABL expression in ET, PV, MF, and CMML patients
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: ALL-type chimeric mRNA expression
Number of subjects: 66
Study: 8676115

Group type: EXPERIMENTAL
Intervention: Cemented total hip arthroplasty
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Cementless total hip arthroplasty
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (Cemented)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (Cementless)
Number of subjects: 147
Study: 2065470

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (n = 11) - graded walk‐jog programme to greater than 60% age‐predicted maximum heart rate, 45 min sessions, three times each week
Number of subjects: 19

Group type: COMPARATOR
Intervention: Light intensity exercise (control group, n = 8) - flexibility (stretching exercises) and walking to less than 60% age‐predicted HRmax, 45 min sessions, three times each week
Number of subjects: 19
Study: 525982

Group type: EXPERIMENTAL
Intervention: Levamisole (three different doses)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 30870290

Group type: EXPERIMENTAL
Intervention: Force of stream
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard fill voiding trial
Number of subjects: 174
Study: 28086848

Group type: EXPERIMENTAL
Intervention: Parents as Agents of Change (PAC©) intervention, a manualized, 16-session, group-based, health care professional-led intervention for parents
Number of subjects: 0
Study: 25120110

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) supplementation (980 mg polyphenols daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 16